Publications by authors named "M Garty"
Cladribine tablets (Mavenclad) were approved by the European Union in 2017 as high-efficacy therapy for highly active relapsing-remitting multiple sclerosis. In Israel, Mavenclad was approved in 2018. Real-life experience has confirmed the efficacy of cladribine tablets over at least 4 years from the initial course.
View Article and Find Full Text PDFArticle Synopsis
- Immune semaphorins, specifically sema3A and sema4A, play a significant role in autoimmune diseases, particularly Multiple Sclerosis (MS).
- In MS patients, sema3A expression on T regulatory cells is significantly decreased, while serum levels of sema4A are increased compared to healthy individuals, indicating a dysregulation in these molecules.
- The study suggests that sema3A functions as a regulatory molecule and sema4A as a stimulatory one in the context of MS, highlighting their potential as therapeutic targets for treatment.
The relationship between triglyceridemia and diabetes mellitus remains unclear. This study evaluated the risk of diabetes and impaired fasting glucose associated with a wide range of triglyceride levels. A longitudinal retrospective study was carried out employing data from a screening center between the years 2000 and 2012.
View Article and Find Full Text PDFPurpose: To assess the possibility of a relationship between body mass index (BMI) and intraocular pressure (IOP) in both men and women.
Materials And Methods: A retrospective cross-sectional analysis of a database from a screening center in Israel which assessed 18,575 subjects, within an age range 20 to 80 years.
Results: The mean (±SD) age of the study sample was 46 (±10) years, 68% were men.
Background And Objectives: We aimed to find predictors for development of anemia in a large cohort of adults.
Patients And Methods: Cohort study of a large health database from a screening center at the Rabin Medical Center in Israel, between the years 2000-2013. We asked which variables, known at the first visit, would predict anemia at the last visit.